OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices for tumor immunotherapy.
OriCell Therapeutics develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 1, 2022 | Series B | $120M | 4 | — | — | Detail |
Jan 18, 2021 | Series A | ¥200M | 1 | — | — | Detail |
Jun 12, 2018 | Angel | ¥3M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Suzhou Fund | — | Series B |
Boquan Equity Investment Management | — | Series B |
J One Capital | — | Series B |
Shanghai Sci-Tech Innovation Center Capital | — | Series B |
Shanghai Gaosen Asset Management | — | Series A |
Suishi Ziben | — | Angel |